A new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey ...

Boehringer Ingelheim, the UK Respiratory Gene Therapy Consortium (GTC), IP Group and Oxford BioMedica (OXB) have commenced ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their mutation type, is being tested in human trials in the UK and Europe.

Boehringer Ingelheim, IP Group, UK Respiratory Gene Therapy Consortium, and OXB launched the first-in-human clinical trial, known as LENTICLAIR 1.

Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...

The effect of cystic fibrosis on many organs and the frequent lung infections means that it is mostly diagnosed in childhood.

Louise Patterson, from Bray, is the mother of Aaron, who will soon be 12. His rare gene means he is currently excluded from modulator therapy Kaftrio, which, when combined with other medication ...

And he’d lost so much weight, none of his old clothes fit — likely, the doctors said, because taking in less oxygen limited his exertion, thus lessening his appetite. Pulmonary fibrosis is considered ...

Sophie out on the boat ahead of her pioneering rowing journey with cystic fibrosis (Supplied) Therapy sessions were offered as part of her cystic fibrosis treatment at Cardiff. At first ...

That’s why it’s counterintuitive to think low oxygen could be a therapy for chronic conditions ranging from mitochondrial diseases and autoimmune disorders to Parkinson’s and even aging.